Telix Pharmaceuticals Limited
TLX
$9.08
-$0.28-2.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 0.00% | -117.36% | -2.75% | -10.65% | -35.71% |
| Total Depreciation and Amortization | 0.00% | 240.50% | -2.75% | -9.11% | 90.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | -63.23% | -2.75% | 39.35% | 215.81% |
| Change in Net Operating Assets | -- | -- | 2.75% | -- | -- |
| Cash from Operations | 0.00% | 589.92% | -2.75% | -93.28% | 446.91% |
| Capital Expenditure | 0.00% | -6.23% | 2.75% | -118.19% | 5.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00% | -2,976.35% | 2.75% | 75.35% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00% | 49.38% | 2.75% | -207.54% | -73.06% |
| Cash from Investing | 0.00% | -344.68% | 2.75% | -22.23% | -317.77% |
| Total Debt Issued | -- | -- | 0.00% | 32,878.49% | -17.26% |
| Total Debt Repaid | 0.00% | -84.66% | 0.00% | -23.82% | -- |
| Issuance of Common Stock | 0.00% | 85.21% | 0.00% | -41.36% | 90.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00% | -494.84% | 166.72% |
| Cash from Financing | 0.00% | -100.70% | -2.75% | 8,791.03% | 349.06% |
| Foreign Exchange rate Adjustments | 0.00% | -57.22% | -2.75% | 632.00% | -187.80% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.00% | -160.41% | -2.75% | 4,118.74% | -1,317.39% |